What does HER2 status mean for Kidney Cancer treatment

HER2 Status and Kidney Cancer Treatment

I appreciate this question, as it touches on an important distinction in cancer care. Let me clarify what HER2 status means—and why it's not typically a major factor in kidney cancer treatment decisions.

HER2 in Different Cancer Types

HER2 (Human Epidermal Growth Factor Receptor 2) is a protein that sits on the surface of cancer cells. It's a well-established biomarker in breast cancer and gastric cancer, where HER2 status directly guides treatment choices.

According to NCCN Guidelines for breast cancer, HER2 testing is performed on all new primary or newly metastatic breast cancers because HER2-positive status opens up specific targeted therapy options like trastuzumab (Herceptin) and pertuzumab.

HER2 and Kidney Cancer: A Different Story

For kidney cancer, HER2 status is NOT a standard biomarker that drives treatment decisions. Here's why:

The NCCN Guidelines for Kidney Cancer (Version 1.2026) focus on different factors when determining treatment:

• Histology type (clear cell vs. non-clear cell)
• Stage of disease (localized vs. metastatic)
• Prognostic risk factors like hemoglobin levels, calcium levels, and time from diagnosis to treatment
• Specific genetic mutations (for hereditary kidney cancer syndromes like VHL, HLRCC, or SDHB-deficient RCC)

What Actually Guides Kidney Cancer Treatment

According to NCCN Guidelines, treatment decisions for kidney cancer typically involve:

For early-stage disease:

• Partial or radical nephrectomy (surgical removal)
• Percutaneous ablation (destroying tumors with heat/cold)
• SBRT (stereotactic body radiation therapy)

For advanced/metastatic disease:

• Immunotherapy combinations like ipilimumab + nivolumab (now a Category 1 preferred recommendation for clear cell kidney cancer)
• Targeted therapies like tyrosine kinase inhibitors (sunitinib, pazopanib, axitinib)
• Clinical trials

Questions to Ask Your Kidney Cancer Team

If you've had HER2 testing done or are wondering about biomarkers for your kidney cancer:

1. "What is my kidney cancer histology type (clear cell or non-clear cell), and how does that affect my treatment options?"
2. "What prognostic risk factors are most relevant to my case?"
3. "Have I been tested for any genetic mutations that might affect my treatment?"
4. "Why was HER2 testing ordered for me, and how will the results be used in my care plan?"
5. "What are the first-line treatment options recommended for my specific stage and type of kidney cancer?"

Bottom Line

While HER2 is a crucial biomarker in breast and gastric cancers, it's not a standard decision-making tool for kidney cancer. If your doctor ordered HER2 testing, ask them specifically how they plan to use those results—there may be a clinical reason specific to your case that's worth understanding.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.